{
    "hands_on_practices": [
        {
            "introduction": "The journey of interpreting a genetic variant begins with a fundamental question: how common is it? This exercise  provides hands-on practice in calculating the Minor Allele Frequency ($MAF$), a cornerstone metric in population genetics and a critical first step in clinical variant analysis. By working through this scenario, you will learn to assess a variant's rarity using definitions and data bins modeled on large-scale genomic databases like the Genome Aggregation Database (gnomAD).",
            "id": "4341305",
            "problem": "A cohort-based allele frequency assessment is being performed for an autosomal single-nucleotide variant in a population-scale dataset used for precision medicine. Consider the following scientifically realistic setting:\n\n- There are $10{,}000$ unrelated diploid human genomes, each contributing $2$ alleles at an autosomal locus. There are no missing genotypes and no copy-number alterations affecting the locus.\n- Across all chromosomes sampled in the cohort, the alternate allele is observed $50$ times.\n- Use the canonical definition of allele frequency: for any allele at a locus, its frequency in the cohort equals the count of that allele divided by the total number of alleles assayed at that locus.\n- The minor allele frequency is defined as the frequency of the less common allele among the reference and alternate alleles at that locus in the cohort.\n- For categorizing rarity, use the following Genome Aggregation Database (gnomAD)-style frequency bins, indexed by $1,2,3,4,5$:\n  - Bin $1$ (extremely rare): $0 < \\mathrm{MAF} < 10^{-4}$.\n  - Bin $2$ (very rare): $10^{-4} \\le \\mathrm{MAF} < 10^{-3}$.\n  - Bin $3$ (rare): $10^{-3} \\le \\mathrm{MAF} < 10^{-2}$.\n  - Bin $4$ (low-frequency): $10^{-2} \\le \\mathrm{MAF} < 10^{-1}$.\n  - Bin $5$ (common): $10^{-1} \\le \\mathrm{MAF} \\le 5 \\times 10^{-1}$.\n\nStarting only from these fundamental definitions and facts, compute the minor allele frequency for this variant and determine its rarity category by bin index using the bins above. Express the minor allele frequency as a decimal and round your result to four significant figures. Provide your final answer as a row matrix $\\begin{pmatrix} a & b \\end{pmatrix}$ where $a$ is the rounded minor allele frequency and $b$ is the integer bin index.",
            "solution": "The problem states an autosomal locus in a cohort of $10{,}000$ diploid genomes. For an autosomal locus, each diploid genome contributes $2$ alleles, so the total number of alleles assayed is\n$$\n2N = 2 \\times 10{,}000 = 20{,}000.\n$$\nThe alternate allele count is given as $50$. By the definition of allele frequency, the alternate allele frequency is\n$$\n\\mathrm{AF}_{\\text{alt}} = \\frac{50}{20{,}000} = 0.0025.\n$$\nThe reference allele frequency must sum with the alternate allele frequency to one, because there are only two alleles considered at the locus and no missing data:\n$$\n\\mathrm{AF}_{\\text{ref}} = 1 - \\mathrm{AF}_{\\text{alt}} = 1 - 0.0025 = 0.9975.\n$$\nThe minor allele frequency (MAF) is defined as the frequency of the less common allele among the two. Therefore,\n$$\n\\mathrm{MAF} = \\min\\{ \\mathrm{AF}_{\\text{alt}}, \\mathrm{AF}_{\\text{ref}} \\} = \\min\\{0.0025, 0.9975\\} = 0.0025.\n$$\nWe must round the minor allele frequency to four significant figures and express it as a decimal. The exact value $0.0025$ has two significant figures; to present four significant figures in decimal form, we retain trailing zeros:\n$$\n\\mathrm{MAF}_{\\text{rounded}} = 0.002500.\n$$\nNext, classify this $\\mathrm{MAF}$ using the specified Genome Aggregation Database (gnomAD)-style bins. We note that\n$$\n0.0025 = 2.5 \\times 10^{-3},\n$$\nwhich satisfies\n$$\n10^{-3} \\le 0.0025 < 10^{-2}.\n$$\nTherefore, it falls into Bin $3$ (rare).\n\nThe requested final answer format is a row matrix with the rounded minor allele frequency and the integer bin index:\n$$\n\\begin{pmatrix}\n0.002500 & 3\n\\end{pmatrix}.\n$$",
            "answer": "$$\\boxed{\\begin{pmatrix}0.002500 & 3\\end{pmatrix}}$$"
        },
        {
            "introduction": "While a variant's rarity is a crucial starting point, a definitive clinical classification requires integrating multiple, independent lines of evidence. This practice  demonstrates how to apply the formal Bayesian framework endorsed by the American College of Medical Genetics and Genomics (ACMG) to synthesize disparate data points. You will transform qualitative evidence strengths into quantitative likelihood ratios to calculate a posterior probability of pathogenicity, mirroring the rigorous process used in modern diagnostic laboratories.",
            "id": "4341303",
            "problem": "A laboratory is evaluating a single-nucleotide variant in a gene with an established autosomal dominant disease mechanism. The variant is a canonical stop-gain change early in the coding sequence, specifically a cytosine-to-thymine transition at position $c.412\\mathrm{C} \\to \\mathrm{T}$ producing $p.\\mathrm{Arg}138^{*}$ in a gene where heterozygous loss of function is a well-established mechanism of disease. Aggregated submissions to the Clinical Variant database (ClinVar) document the variant in $k = 8$ unrelated probands with a highly specific and concordant phenotype for the gene-associated disorder. A large control cohort from the Genome Aggregation Database (gnomAD) comprising $N_{0} = 250{,}000$ alleles shows $0$ observations of this variant and no homozygotes. Multiple independent in silico tools predict the variant to be deleterious due to introduction of a premature termination codon that is expected to trigger nonsense-mediated decay. Assume that the observed case enrichment, rarity in controls, and mechanistic plausibility together satisfy one very strong, one strong, one moderate, and one supporting American College of Medical Genetics and Genomics (ACMG) pathogenic criteria, respectively, under standard laboratory practice, and that no benign criteria are met.\n\nAdopt a Bayesian classification framework for ACMG criteria as recommended by the ClinGen Sequence Variant Interpretation (SVI) Working Group, and assume a prior probability of pathogenicity $P_{\\mathrm{prior}} = \\frac{1}{19}$ for a randomly selected rare missense or truncating variant in this gene. Using Bayesâ€™ theorem and treating the ACMG evidence categories as conditionally independent for the purposes of likelihood combination, compute the posterior probability of pathogenicity $P_{\\mathrm{post}}$ for this variant. Round your final numeric answer to four significant figures and express it as a unitless decimal (do not use a percentage sign).",
            "solution": "The problem requires the calculation of the posterior probability of pathogenicity for a genetic variant, $P_{\\mathrm{post}}$, using a Bayesian framework. The calculation begins with a prior probability and updates it based on several pieces of evidence. The most efficient way to combine evidence in this framework is to use the odds formulation of Bayes' theorem.\n\nThe posterior odds of an event are the product of the prior odds and the likelihood ratio(s) from the evidence:\n$$ \\text{Odds}(\\text{Pathogenic}|\\text{Evidence}) = \\text{Odds}(\\text{Pathogenic}) \\times \\text{LR}(\\text{Evidence}) $$\nwhere $\\text{Odds}(A) = \\frac{P(A)}{1 - P(A)}$, and LR is the likelihood ratio.\n\nFirst, we convert the given prior probability, $P_{\\mathrm{prior}}$, into prior odds.\n$$ P_{\\mathrm{prior}} = P(\\text{Pathogenic}) = \\frac{1}{19} $$\nThe prior odds of pathogenicity are:\n$$ \\text{Odds}_{\\mathrm{prior}} = \\frac{P_{\\mathrm{prior}}}{1 - P_{\\mathrm{prior}}} = \\frac{\\frac{1}{19}}{1 - \\frac{1}{19}} = \\frac{\\frac{1}{19}}{\\frac{18}{19}} = \\frac{1}{18} $$\n\nNext, we identify the likelihood ratios associated with each piece of evidence. The problem states that the variant meets one very strong, one strong, one moderate, and one supporting pathogenic criterion. The ClinGen SVI working group has calibrated these evidence strengths to specific quantitative likelihood ratios, termed Odds of Pathogenicity (OddsPath):\n-   Very Strong (VS) evidence corresponds to an OddsPath of $350:1$, so $LR_{\\mathrm{VS}} = 350$.\n-   Strong (S) evidence corresponds to an OddsPath of $18.7:1$, so $LR_{\\mathrm{S}} = 18.7$.\n-   Moderate (M) evidence corresponds to an OddsPath of $4.3:1$, so $LR_{\\mathrm{M}} = 4.3$.\n-   Supporting (P) evidence corresponds to an OddsPath of $2.08:1$, so $LR_{\\mathrm{P}} = 2.08$.\n\nThe problem states we can assume conditional independence, which means the total likelihood ratio for the combined evidence, $LR_{\\mathrm{total}}$, is the product of the individual likelihood ratios:\n$$ LR_{\\mathrm{total}} = LR_{\\mathrm{VS}} \\times LR_{\\mathrm{S}} \\times LR_{\\mathrm{M}} \\times LR_{\\mathrm{P}} $$\n$$ LR_{\\mathrm{total}} = 350 \\times 18.7 \\times 4.3 \\times 2.08 $$\nCalculating this product:\n$$ LR_{\\mathrm{total}} = 6545 \\times 8.944 = 58533.08 $$\n\nNow, we can calculate the posterior odds of pathogenicity by multiplying the prior odds by the total likelihood ratio:\n$$ \\text{Odds}_{\\mathrm{post}} = \\text{Odds}_{\\mathrm{prior}} \\times LR_{\\mathrm{total}} $$\n$$ \\text{Odds}_{\\mathrm{post}} = \\frac{1}{18} \\times 58533.08 \\approx 3251.8378 $$\n\nFinally, we convert the posterior odds back into a probability, $P_{\\mathrm{post}}$. The relationship between probability $P$ and odds $O$ is $P = \\frac{O}{1 + O}$.\n$$ P_{\\mathrm{post}} = \\frac{\\text{Odds}_{\\mathrm{post}}}{1 + \\text{Odds}_{\\mathrm{post}}} $$\n$$ P_{\\mathrm{post}} = \\frac{3251.8378}{1 + 3251.8378} = \\frac{3251.8378}{3252.8378} \\approx 0.99969259 $$\n\nThe problem requires the final answer to be rounded to four significant figures.\n$$ P_{\\mathrm{post}} \\approx 0.9997 $$\nThis result indicates that the probability of the variant being pathogenic is greater than $99.9\\%$, which according to the ACMG/AMP guidelines, is sufficient to classify the variant as \"Pathogenic\".",
            "answer": "$$\\boxed{0.9997}$$"
        },
        {
            "introduction": "Precision medicine finds one of its most powerful applications in oncology, but interpreting genomic data from tumors introduces unique complexities. This advanced practice  delves into the analysis of somatic variants from a mixed tumor-normal sample, a common real-world scenario. You will learn to model how factors like tumor purity and chromosomal copy number changes affect the observed variant allele fraction ($VAF$) and use Bayesian inference to determine the most probable underlying tumor biology from sequencing data.",
            "id": "4341294",
            "problem": "A tumor biopsy is profiled by targeted Next-Generation Sequencing (NGS). The sample consists of a mixture of tumor and normal cells, with tumor purity $p=0.6$. At a locus of interest, there is a clonal somatic single-nucleotide variant that is heterozygous in tumor cells, meaning the variant resides on exactly $c=1$ of the homologous chromosomes in every tumor cell. Normal cells are diploid. Sequencing at the locus yields $n=1000$ total reads, of which $x=280$ carry the variant allele.\n\nUse the following foundational bases:\n- In a mixture of cell populations, the expected variant allele fraction (VAF) equals the fraction of mutant alleles among all alleles contributing to the sample, assuming unbiased sequencing with respect to allele identity.\n- The number of alleles contributed by a cell equals its total copy number at the locus.\n- Each sequenced read can be modeled as an independent Bernoulli trial that reports the variant allele with probability equal to the underlying expected VAF at the locus.\n\nConsider two hypotheses for the tumor copy-number state at the locus:\n- Hypothesis $\\mathcal{H}_{N}$ (neutral): tumor cells are copy-number neutral (diploid total copy number $t=2$).\n- Hypothesis $\\mathcal{H}_{G}$ (gain): tumor cells carry a single-copy gain at the locus (trisomy total copy number $t=3$), and the variant remains present on only one tumor copy.\n\nNormal cells are diploid under both hypotheses. Derive the expected variant-allele probability $\\theta$ under each hypothesis from first principles of mixture contributions and allele counting. Then, using the binomial model for $x$ given $\\theta$, compute the Bayes factor favoring $\\mathcal{H}_{N}$ over $\\mathcal{H}_{G}$ and the posterior probability $P(\\mathcal{H}_{N} \\mid \\text{data})$ assuming equal prior probabilities for $\\mathcal{H}_{N}$ and $\\mathcal{H}_{G}$.\n\nReport the posterior probability for $\\mathcal{H}_{N}$ as a decimal, and round your answer to four significant figures.",
            "solution": "The problem is well-posed, scientifically grounded, and provides all necessary information to derive a unique solution. The core of the problem involves calculating the expected variant allele fraction (VAF) under two different biological hypotheses and then using Bayesian inference to determine which hypothesis is better supported by the sequencing data.\n\nThe first step is to derive a general formula for the expected VAF, which we denote as $\\theta$. The sample is a mixture of tumor cells (at a fraction, or purity, of $p$) and normal cells (at a fraction of $1-p$). The VAF is the ratio of the number of variant (mutant) alleles to the total number of alleles at the locus of interest, aggregated across the entire cell population.\n\nLet $c$ be the number of copies of the variant allele in a single tumor cell.\nLet $t$ be the total copy number (total number of alleles) at the locus in a single tumor cell.\nLet $t_{norm}$ be the total copy number at the locus in a single normal cell. The problem states normal cells are diploid, so $t_{norm}=2$.\nThe variant is somatic, so normal cells do not carry it.\n\nThe total number of variant alleles in a representative sample is proportional to $p \\cdot c$.\nThe total number of alleles from tumor cells is proportional to $p \\cdot t$.\nThe total number of alleles from normal cells is proportional to $(1-p) \\cdot t_{norm}$.\nThe expected VAF, $\\theta$, is therefore:\n$$\n\\theta = \\frac{p \\cdot c}{p \\cdot t + (1-p) \\cdot t_{norm}}\n$$\nWe are given the following values: tumor purity $p=0.6$, variant copy number in tumor cells $c=1$, and total reads $n=1000$ with $x=280$ variant reads.\n\nNow, we calculate the expected VAF, $\\theta$, for each hypothesis.\n\nUnder hypothesis $\\mathcal{H}_{N}$ (copy-number neutral):\nThe tumor cells are diploid, so their total copy number is $t=2$.\n$$\n\\theta_N = \\frac{p \\cdot c}{p \\cdot t + (1-p) \\cdot t_{norm}} = \\frac{0.6 \\cdot 1}{0.6 \\cdot 2 + (1-0.6) \\cdot 2} = \\frac{0.6}{1.2 + 0.8} = \\frac{0.6}{2} = 0.3\n$$\n\nUnder hypothesis $\\mathcal{H}_{G}$ (single-copy gain):\nThe tumor cells have a total copy number of $t=3$. The variant remains on $c=1$ copy.\n$$\n\\theta_G = \\frac{p \\cdot c}{p \\cdot t + (1-p) \\cdot t_{norm}} = \\frac{0.6 \\cdot 1}{0.6 \\cdot 3 + (1-0.6) \\cdot 2} = \\frac{0.6}{1.8 + 0.8} = \\frac{0.6}{2.6} = \\frac{6}{26} = \\frac{3}{13}\n$$\nNumerically, $\\theta_G \\approx 0.230769$.\n\nThe observed VAF from the data is $\\frac{x}{n} = \\frac{280}{1000} = 0.28$. This value is closer to $\\theta_N$ than to $\\theta_G$, suggesting that $\\mathcal{H}_N$ is the more likely hypothesis. We will quantify this using a Bayes factor.\n\nThe problem states that the number of variant reads, $x$, can be modeled by a binomial distribution with $n$ trials and success probability $\\theta$. The likelihood of observing $x$ variant reads is:\n$$\nP(x \\mid n, \\theta) = \\binom{n}{x} \\theta^x (1-\\theta)^{n-x}\n$$\nThe Bayes factor, $BF_{NG}$, favoring hypothesis $\\mathcal{H}_{N}$ over $\\mathcal{H}_{G}$ is the ratio of the likelihoods of the data under each hypothesis:\n$$\nBF_{NG} = \\frac{P(\\text{data} \\mid \\mathcal{H}_{N})}{P(\\text{data} \\mid \\mathcal{H}_{G})} = \\frac{P(x \\mid n, \\theta_N)}{P(x \\mid n, \\theta_G)}\n$$\nSubstituting the binomial probability mass function:\n$$\nBF_{NG} = \\frac{\\binom{n}{x} \\theta_N^x (1-\\theta_N)^{n-x}}{\\binom{n}{x} \\theta_G^x (1-\\theta_G)^{n-x}} = \\left(\\frac{\\theta_N}{\\theta_G}\\right)^x \\left(\\frac{1-\\theta_N}{1-\\theta_G}\\right)^{n-x}\n$$\nWe substitute the known values: $n=1000$, $x=280$, $n-x=720$, $\\theta_N=0.3$, and $\\theta_G=\\frac{3}{13}$.\n$$\nBF_{NG} = \\left(\\frac{0.3}{3/13}\\right)^{280} \\left(\\frac{1-0.3}{1-3/13}\\right)^{720} = \\left(\\frac{0.3 \\cdot 13}{3}\\right)^{280} \\left(\\frac{0.7}{10/13}\\right)^{720}\n$$\n$$\nBF_{NG} = \\left(\\frac{3.9}{3}\\right)^{280} \\left(\\frac{0.7 \\cdot 13}{10}\\right)^{720} = (1.3)^{280} (0.91)^{720}\n$$\nTo compute this, we use logarithms to avoid numerical overflow:\n$$\n\\ln(BF_{NG}) = \\ln\\left((1.3)^{280} (0.91)^{720}\\right) = 280\\ln(1.3) + 720\\ln(0.91)\n$$\nUsing standard values for natural logarithms, $\\ln(1.3) \\approx 0.262364$ and $\\ln(0.91) \\approx -0.094311$.\n$$\n\\ln(BF_{NG}) \\approx 280(0.262364) + 720(-0.094311) \\approx 73.46192 - 67.90392 \\approx 5.558\n$$\nThe Bayes factor is then:\n$$\nBF_{NG} = \\exp(\\ln(BF_{NG})) \\approx \\exp(5.558) \\approx 259.3\n$$\nThis large value indicates strong evidence in favor of hypothesis $\\mathcal{H}_N$.\n\nFinally, we compute the posterior probability of $\\mathcal{H}_N$, denoted $P(\\mathcal{H}_N \\mid \\text{data})$. The relationship between posterior odds, prior odds, and the Bayes factor is:\n$$\n\\frac{P(\\mathcal{H}_N \\mid \\text{data})}{P(\\mathcal{H}_G \\mid \\text{data})} = \\frac{P(\\mathcal{H}_N)}{P(\\mathcal{H}_G)} \\times BF_{NG}\n$$\nThe problem states to assume equal prior probabilities, so $P(\\mathcal{H}_N) = P(\\mathcal{H}_G) = 0.5$. The prior odds ratio $\\frac{P(\\mathcal{H}_N)}{P(\\mathcal{H}_G)} = 1$.\nTherefore, the posterior odds are equal to the Bayes factor:\n$$\n\\frac{P(\\mathcal{H}_N \\mid \\text{data})}{P(\\mathcal{H}_G \\mid \\text{data})} = BF_{NG}\n$$\nLet $P_N = P(\\mathcal{H}_N \\mid \\text{data})$. Since the two hypotheses are mutually exclusive and exhaustive in this context, $P(\\mathcal{H}_G \\mid \\text{data}) = 1 - P_N$.\n$$\n\\frac{P_N}{1-P_N} = BF_{NG}\n$$\nSolving for $P_N$:\n$$\nP_N = BF_{NG}(1-P_N) \\implies P_N = BF_{NG} - P_N \\cdot BF_{NG} \\implies P_N(1+BF_{NG}) = BF_{NG}\n$$\n$$\nP_N = P(\\mathcal{H}_N \\mid \\text{data}) = \\frac{BF_{NG}}{1+BF_{NG}}\n$$\nUsing a more precise calculation for the Bayes factor:\n$\\ln(BF_{NG}) = 280\\ln(1.3) + 720\\ln(0.91) \\approx 5.558305$.\n$BF_{NG} = \\exp(5.558305) \\approx 259.3585$.\nSubstituting this into the formula for the posterior probability:\n$$\nP(\\mathcal{H}_N \\mid \\text{data}) = \\frac{259.3585}{1+259.3585} = \\frac{259.3585}{260.3585} \\approx 0.996159\n$$\nRounding the result to four significant figures gives $0.9962$.",
            "answer": "$$\n\\boxed{0.9962}\n$$"
        }
    ]
}